Literature DB >> 20238114

Alpha-type 1-polarized dendritic cells loaded with apoptotic allogeneic myeloma cell line induce strong CTL responses against autologous myeloma cells.

Deok-Hwan Yang1, Mi-Hyun Kim, Cheol Yi Hong, Youn-Kyung Lee, Chun-Ji Jin, Thanh-Nhan Nguyen Pham, Jae-Sook Ahn, Woo-Kyun Bae, Yeo-Kyeoung Kim, Ik-Joo Chung, Hyeoung-Joon Kim, Pawel Kalinski, Je-Jung Lee.   

Abstract

To induce a potent cytotoxic T lymphocyte (CTL) response, various tumor antigens should be loaded onto dendritic cells (DCs). In multiple myeloma (MM), it is difficult to obtain a sufficient number of autologous tumor cells as a source of tumor antigens in the clinical setting. We investigated the feasibility of immunotherapy in patients with MM, using myeloma-specific CTLs generated in vitro by alpha-type 1-polarized DCs (alphaDC1s) loaded with the ultraviolet B-irradiated allogeneic myeloma cell line, ARH77. alphaDC1s significantly increased the expression of several costimulatory molecules without differences in loading with tumor antigens. alphaDC1s showed a high production of interleukin-12 during maturation and after subsequent stimulation with CD40L but were not significantly affected by loading tumor antigens. Myeloma-specific CTLs against autologous myeloma cells from MM patients were induced by alphaDC1s pulsed with apoptotic ARH77 cells. Our data indicate that autologous DCs loaded with an allogeneic myeloma cell line can generate potent myeloma-specific CTL responses against autologous myeloma cells and might provide a practical method for cellular immunotherapy in patients with MM.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20238114     DOI: 10.1007/s00277-010-0931-3

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  12 in total

1.  Feasibility of dendritic cell-based vaccine against glioblastoma by using cytoplasmic transduction peptide (CTP)-fused protein antigens combined with anti-PD1.

Authors:  Young-Hee Kim; Thi-Anh-Thuy Tran; Thi-Hoang-Oanh Duong; Shin Jung; In-Young Kim; Kyung-Sub Moon; Woo-Youl Jang; Hyun-Ju Lee; Je-Jung Lee; Tae-Young Jung
Journal:  Hum Vaccin Immunother       Date:  2020-05-13       Impact factor: 3.452

Review 2.  Multiple myeloma in Korea: past, present, and future perspectives. Experience of the Korean Multiple Myeloma Working Party.

Authors:  Jae Hoon Lee; Dong Soon Lee; Je Jung Lee; Yoon Hwan Chang; Jong Youl Jin; Deog-Yeon Jo; Soo Mee Bang; Hyo Jung Kim; Jin Seok Kim; Kihyun Kim; Hyeon Seok Eom; Chang Ki Min; Sung Soo Yoon; Sun Hee Kim; Cheolwon Suh; Kyung Sam Cho
Journal:  Int J Hematol       Date:  2010-06-11       Impact factor: 2.490

3.  Optimal culture conditions for the generation of natural killer cell-induced dendritic cells for cancer immunotherapy.

Authors:  Thanh-Nhan Nguyen-Pham; Deok-Hwan Yang; Truc-Anh Thi Nguyen; Mi-Seon Lim; Cheol Yi Hong; Mi-Hyun Kim; Hyun Ju Lee; Youn-Kyung Lee; Duck Cho; Soo-Young Bae; Jae-Sook Ahn; Yeo-Kyeoung Kim; Ik-Joo Chung; Hyeoung-Joon Kim; Je-Jung Lee
Journal:  Cell Mol Immunol       Date:  2011-08-08       Impact factor: 11.530

Review 4.  Immunotherapeutic potential of oncolytic vaccinia virus.

Authors:  Steve H Thorne
Journal:  Immunol Res       Date:  2011-08       Impact factor: 4.505

Review 5.  Novel strategies for immunotherapy in multiple myeloma: previous experience and future directions.

Authors:  Ivetta Danylesko; Katia Beider; Avichai Shimoni; Arnon Nagler
Journal:  Clin Dev Immunol       Date:  2012-05-10

Review 6.  Immunotherapy using dendritic cells against multiple myeloma: how to improve?

Authors:  Thanh-Nhan Nguyen-Pham; Yoon-Kyung Lee; Hyeoung-Joon Kim; Je-Jung Lee
Journal:  Clin Dev Immunol       Date:  2012-03-15

7.  Cellular immunotherapy using dendritic cells against multiple myeloma.

Authors:  Thanh-Nhan Nguyen-Pham; Youn-Kyung Lee; Hyun-Ju Lee; Mi-Hyun Kim; Deok-Hwan Yang; Hyeoung-Joon Kim; Je-Jung Lee
Journal:  Korean J Hematol       Date:  2012-03-28

Review 8.  Recent advances in multiple myeloma: a Korean perspective.

Authors:  Junshik Hong; Jae Hoon Lee
Journal:  Korean J Intern Med       Date:  2016-09-01       Impact factor: 2.884

Review 9.  Dendritic Cell-Based Cancer Immunotherapy against Multiple Myeloma: From Bench to Clinic.

Authors:  My-Dung Hoang; Sung-Hoon Jung; Hyun-Ju Lee; Youn-Kyung Lee; Thanh-Nhan Nguyen-Pham; Nu-Ri Choi; Manh-Cuong Vo; Seung-Shin Lee; Jae-Sook Ahn; Deok-Hwan Yang; Yeo-Kyeoung Kim; Hyeoung-Joon Kim; Je-Jung Lee
Journal:  Chonnam Med J       Date:  2015-04-14

10.  Complex evaluation of human monocyte-derived dendritic cells for cancer immunotherapy.

Authors:  Katerina Vopenkova; Klara Mollova; Ivana Buresova; Jaroslav Michalek
Journal:  J Cell Mol Med       Date:  2012-11       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.